MEDICATIONS FOR ERADICATION OF HELICOBACTER PYLORI (REVIEW).

Autor: Zazadze R; Tbilisi State Medical University, 1Department of Pharmaceutical Technologies; Georgia., Bakuridze L; Tbilisi State Medical University, 1Department of Pharmaceutical Technologies; Georgia., Gongadze N; Tbilisi State Medical University, 2Department of Medical Pharmacology; Georgia., Tutberidze P; 3Javakhishvili Tbilisi State University, Department of Clinical Surgery, Georgia., Kiladze M; 3Javakhishvili Tbilisi State University, Department of Clinical Surgery, Georgia.
Jazyk: angličtina
Zdroj: Georgian medical news [Georgian Med News] 2022 Jan (322), pp. 162-166.
Abstrakt: Helicobacter pylori is a pathogenic microorganism that causes gastritis, duodenitis, peptic ulcer disease of the stomach and duodenum. Recent data confirm the close association of Helicobacter pylori with the development of gastric cancer. Due to the failure of standard H. pylori eradication regimens, intensive studies are being conducted to develop targeted local delivery and prolonging activity drug forms. Based on scientific studies, sufficient knowledge has been accumulated on the inhibitory action of biologically active substances of plant origin: peptides, polyphenols, terpenes, fatty acids on Helicobacter pylori, which allows developing an alternative treatment scheme. It is especially important today to create local and long-acting, high-density, mucoadhesive, floating and swelling systems. Unlike other forms of medicine, foam systems are interesting in this respect. They are distinguished by a large touch surface, high bioavailability and rapid therapeutic effect. Foam provides economical dosing, better contact with the mucous membrane, and give the drug a prolonged action. Under the influence of body temperature the foam increases in volume, filling all free spaces and channels. However, the foam can provide high concentrations of the medicinal substance for up to 4 hours.
Databáze: MEDLINE